Description
PrymaLab · Research Use Only
Cerebrolysin 60mg
Defined by how it is made · not by what it is
Every other article in this catalogue is a molecule with a sequence and a mass. Cerebrolysin is not. It is a mixture produced by breaking porcine brain protein down with enzymes, and it is defined by how that is done rather than by what comes out.
Specification Table
| Property | Value |
|---|---|
| Article type | Peptide preparation, not a defined chemical entity |
| Source material | Purified porcine brain protein |
| Production route | Standardised enzymatic hydrolysis |
| What that yields | A mixture of low molecular weight peptides and free amino acids |
| Approximate split reported | Around 15 percent peptide fraction and 85 percent free amino acids |
| Size ceiling on the peptide fraction | Below 10 kDa |
| CAS | None given. A process-defined mixture does not have a single registry identity |
| Molecular weight | Not applicable. The article is a distribution rather than one species |
| Approved product format | An aqueous concentrate supplied in ampoules at 215.2 mg per millilitre |
| Approved product manufacturer | EVER Neuro Pharma, Austria |
| Relationship to that product | Material supplied here is not that product and is not manufactured to pharmaceutical standards |
| Species origin consideration | Porcine. Animal-derived material carries documentation requirements synthetic peptides do not |
| Purity | Per lot-specific certificate of analysis |
| Storage | Per certificate. Format determines the requirement |
What Is Actually in Cerebrolysin?
What cerebrolysin contains is a distribution, and the useful version of that answer has numbers attached.
Cerebrolysin starts as purified protein from porcine brain tissue, broken down enzymatically under controlled conditions into fragments.
The process is run to a specification that caps the size of what survives, so the peptide content sits below 10 kDa and the large intact proteins are gone.
What comes out is reported as roughly fifteen percent peptides and eighty-five percent free amino acids by mass.
That second figure surprises people. The majority of the material by weight is individual amino acids rather than peptides of any length.
No single component has been identified as carrying the activity attributed to the preparation. The manufacturer position is that the mixture is the article.
That is a defensible position for a biological and it is not the same kind of claim as a single-molecule product makes.
It also means the usual question a buyer asks about cerebrolysin, which is what the purity is, has no meaningful answer.
Purity implies one intended species and a measurable share of everything else. A preparation whose intended content is a mixture has consistency rather than purity. Those are different properties and they are measured differently.
How Do You Verify Something With No Structure?
Every verification argument elsewhere in this catalogue starts from a sequence and a calculated mass. Neither exists here.
What replaces them is a set of process and profile measurements, and a certificate offering none of them is offering nothing at all.
Total nitrogen content is the first. It establishes how much protein-derived material is present at all.
The free amino acid profile is the second, and it is the most informative single measurement available. Quantifying the individual amino acids gives a fingerprint that a correctly made preparation reproduces.
A molecular weight distribution is the third, usually by size exclusion chromatography, showing that the peptide fraction sits where it should and that nothing large survived.
A chromatographic profile of the peptide fraction is the fourth. It cannot identify components and it can be compared against a reference profile, which is what consistency means for an article like this.
Species verification is the fifth and it has no equivalent anywhere else in this range. Cerebrolysin is porcine and a buyer is entitled to documentation establishing that.
Microbiological and endotoxin figures are the sixth. Animal-derived material carries a contamination profile that synthetic peptide simply does not.
A supplier who can produce an amino acid profile and a molecular weight distribution has characterised the preparation. One who offers a purity percentage has described it in a vocabulary that does not apply.
What Does the Porcine Origin Change?
Cerebrolysin carries obligations that synthetic material does not, because it is animal-derived, and they are practical rather than philosophical.
Traceability is the first. The species, the source, and ideally the collection and processing controls should be documented, because none of that can be inferred from the material itself.
Consistency between lots is the second, and it is harder to achieve than for a synthetic product. Biological starting material varies in ways a chemical feedstock does not.
The manufacturing process is what absorbs that variation, which is why the process specification matters more here than the input specification.
Contamination profile is the third. Synthetic peptide is made in a reactor and animal-derived material is made from tissue, and the organisms and residues each can carry are entirely different sets.
Endotoxin has a specific relevance for any cell-based work, because it produces real effects that have nothing to do with the article under study.
There is also a question of use restrictions that a researcher should settle before ordering rather than after.
Institutions frequently apply separate approval requirements to animal-derived reagents, and porcine material specifically raises considerations in some settings that a synthetic peptide does not.
None of that is an objection to the preparation. It is a set of questions that ordering a synthetic peptide never raises and ordering this one always should.
One more consideration that applies to any tissue-derived article and rarely appears on a listing.
Documentation of the source herd and of the processing controls is standard for pharmaceutical-grade material and is frequently absent for research-grade equivalents.
Asking for it is reasonable, and a supplier who cannot produce anything is telling you something about how the material was obtained.
What Is the Relationship to the Approved Product?
An approved cerebrolysin product exists and it is worth describing precisely, because the relationship is easy to overstate.
The approved article is an aqueous concentrate supplied in ampoules at 215.2 milligrams per millilitre, manufactured in Austria under pharmaceutical controls, and it holds marketing approval in a number of countries.
It carries a published clinical record, including controlled trials with defined endpoints, which is more than most compounds in this catalogue have.
What is supplied here is research-grade material rather than that product. It is not made to pharmaceutical standards and no equivalence between the two has been shown.
The format difference is worth noting alongside the manufacturing one. The approved article is a solution at a stated concentration, and a research presentation quoted as a mass may not be the same physical form.
That matters because a preparation defined by process is also defined by its final formulation, and changing the format changes the article in a way it would not for a synthetic peptide.
The published trial literature was generated with the approved concentrate at stated volumes.
Applying those figures to research material assumes an equivalence in composition that nothing on a research certificate establishes.
Reading the trials is worthwhile and the caveat travels with them, which is a more useful position than either ignoring the literature or treating it as transferable.
What Does the Trial Record Cover?
This is one of the few articles in this catalogue with a controlled clinical literature attached, and describing it accurately means naming the endpoints.
Randomised controlled trials have been conducted, principally in stroke recovery and in cognitive decline, with defined outcome measures and published results.
Those trials used the approved concentrate at stated volumes over stated periods, under pharmaceutical manufacturing controls.
Results across that literature are mixed rather than uniform, which is the normal state of a clinical evidence base and is often flattened in secondary description.
Some trials reported effects on their primary endpoint and some did not. Meta-analyses have been published and their conclusions depend on which trials were included.
That is a description of a real and contested evidence base rather than a dismissal of it, and it is more useful to a researcher than either enthusiasm or scepticism.
What the record does not contain is any demonstration that research-grade material of this kind reproduces the composition used in those trials.
For a process-defined preparation that gap is wider than it would be for a synthetic molecule, because the article is the process output rather than a structure that can be matched.
A synthetic peptide made by two manufacturers to the same sequence is the same molecule. Two hydrolysates made by different processes are not necessarily the same preparation.
Anyone citing the trial literature alongside research material should state that distinction rather than letting the citation imply an equivalence that has not been established.
How Should It Be Stored and Recorded?
Storing cerebrolysin depends on the format supplied, which is the first thing to establish from the certificate.
A solution and a lyophilised solid have different requirements, and for an article whose definition includes its own formulation the two are not interchangeable.
For a solution, refrigeration and light exclusion are the baseline. Container closure matters too, since an unpreserved aqueous preparation is vulnerable once opened.
For a solid, the usual sealed dry storage applies at 2 to 8 degrees Celsius short term and lower for longer.
In either case freeze-thaw cycling should be avoided, since a mixture has more components able to precipitate or aggregate than a single peptide does.
A cerebrolysin record needs fields the rest of this catalogue does not use.
Alongside lot and date, record the format supplied, the concentration or mass basis, the species documentation reference and any endotoxin figure.
Record the amino acid profile reference too, where the supplier gave one, because that is the closest thing to an identity this article has.
A second laboratory reproducing the work needs those fields, and none of them can be reconstructed from the material after the fact.
One last point about comparing across suppliers.
Two preparations made by different processes are different articles even where both are described the same way, so a supplier change here is a material change rather than a procurement detail.
Published Literature
Selected references on the preparation and on its clinical evaluation.
- Masliah E, Diez-Tejedor E. Drugs of Today. 2012;48 Suppl A:3-24. DOI: 10.1358/dot.2012.48(Suppl.A).1739716
- Muresanu DF, Heiss WD, Hoemberg V, Bajenaru O, Popescu CD, Vester JC, et al. Stroke. 2016;47(1):151-159. DOI: 10.1161/STROKEAHA.115.009416
- Bornstein NM, Guekht A, Vester J, Heiss WD, Gusev E, Homberg V, et al. Neurological Sciences. 2018;39(4):629-640. DOI: 10.1007/s10072-017-3214-0
- Zhang C, Chopp M, Cui Y, Wang L, Zhang R, Zhang L, et al. Journal of Neuroscience Research. 2010;88(15):3275-3281. DOI: 10.1002/jnr.22495
Frequently Asked Questions
What is cerebrolysin?
A peptide preparation rather than a defined chemical entity. It is produced by standardised enzymatic breakdown of purified porcine brain protein, yielding a mixture of low molecular weight peptides and free amino acids.
What is the composition?
Reported as roughly fifteen percent peptides and eighty-five percent free amino acids by mass, with the peptide fraction capped below 10 kDa by the process specification.
Does it have a CAS number?
No. A preparation defined by its manufacturing process rather than by a structure does not have a single registry identity, and quoting one would misrepresent what the article is.
Can it be assigned a molecular weight?
No. The article is a distribution rather than one species, so a molecular weight figure has no meaning here even though certificates sometimes print one.
What about purity?
Purity implies one intended species and a measurable share of everything else. A preparation whose intended content is a mixture has consistency rather than purity, and those are measured differently.
How is it verified then?
Total nitrogen, a free amino acid profile, a molecular weight distribution by size exclusion, a chromatographic profile of the peptide fraction, species documentation, and microbiological and endotoxin figures.
Which of those matters most?
The free amino acid profile. Quantifying the individual amino acids gives a fingerprint that a correctly made preparation reproduces, and it is the closest thing to an identity this article has.
What does the porcine origin change?
Traceability, lot consistency and contamination profile. Biological starting material varies in ways a chemical feedstock does not, and the process is what absorbs that variation.
Why does endotoxin matter here?
Because animal-derived material carries a contamination profile synthetic peptide does not, and endotoxin produces real effects in any cell-based system that have nothing to do with the article under study.
Are there approval requirements to consider?
Frequently. Institutions often apply separate approval requirements to animal-derived reagents, which is a question worth settling before ordering rather than after.
Is there an approved product?
Yes, an aqueous concentrate at 215.2 milligrams per millilitre manufactured in Austria under pharmaceutical controls, holding marketing approval in a number of countries and carrying a published trial record.
Is this that product?
No. Material supplied here is research-grade, is not manufactured to pharmaceutical standards, and no equivalence has been demonstrated. The format may also differ, which matters for an article defined by its formulation.
Compliance Statement
Cerebrolysin is sold exclusively for laboratory research use. It is not a drug, food, or cosmetic product, and it is not a dietary product of any kind. It is not approved by the FDA or any comparable authority for human or veterinary use, it is a preparation defined by its manufacturing process rather than a defined chemical entity so it carries no single registry identity or molecular weight, it is derived from porcine tissue and institutions frequently apply separate approval requirements to animal-derived reagents, material supplied here is not the approved product manufactured under pharmaceutical controls and no equivalence between the two has been demonstrated, and no compound in this range is offered for any human or veterinary purpose. This product is not intended to diagnose, treat, cure, or prevent any disease. It must not be given to humans or animals. Purchase is restricted to qualified researchers and institutions operating within applicable laws. All handling is the responsibility of the purchasing laboratory.
Other formats of Cerebrolysin
Cerebrolysin is also stocked as Cerebrolysin 120mg Nasal Spray. Each listing states its own quantity and concentration, and the pen and vial comparison explains what changes between formats.
19 reviews for Cerebrolysin 60mg